Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909959 · ClinicalTrials.gov registry record · Phase 2
Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02909959 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 48 participants.
The verdict
NCT02909959, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The aim of this randomized controlled trial is to determine if a nutritional supplement containing broccoli sprout and seed extracts, a rich source of sulforaphane, is effective in reducing core symptoms of autism spectrum disorder (ASD). The study will also explore the safety and tolerability of a sulforaphane supplement in young men with ASD, as well as its effects on challenging neuropsychiatric symptoms that are commonly associated with ASD, such as hyperactivity, irritability, and repetitive movements.
Interventions
- DRUG Placebo
- DRUG Sulforaphane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02909959
The ClinicalTrials.gov registry entry for NCT02909959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02909959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02909959 about?
NCT02909959 is a clinical study titled "Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder". The aim of this randomized controlled trial is to determine if a nutritional supplement containing broccoli sprout and seed extracts, a rich source of sulforaphane, is effective in reducing core symptoms of autism spectrum disorder (ASD). The study will also explore the safety and tolerability of a ...
What is the current status of trial NCT02909959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-03-01. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT02909959?
The interventions under investigation include: Placebo (DRUG), Sulforaphane (DRUG).
Who is sponsoring clinical trial NCT02909959?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.